DERMA SCIENCES INC
10QSB, EX-27, 2000-08-14
PHARMACEUTICAL PREPARATIONS
Previous: DERMA SCIENCES INC, 10QSB, 2000-08-14
Next: NEW YORK MUNICIPALS PORTFOLIO, NSAR-A, 2000-08-14



<TABLE> <S> <C>

<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial information extracted from the
registrant's unaudited consolidated financial statements for the six month
period ended June 30, 2000 and is qualified in its entirety by reference to
those financial statements.
</LEGEND>
<CURRENCY>                      U.S. Dollars

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-START>                                  JAN-1-2000
<PERIOD-END>                                   JUN-30-2000
<EXCHANGE-RATE>                                          1
<CASH>                                             870,511
<SECURITIES>                                             0
<RECEIVABLES>                                    1,867,298
<ALLOWANCES>                                             0
<INVENTORY>                                      1,299,750
<CURRENT-ASSETS>                                 4,477,316
<PP&E>                                             330,637
<DEPRECIATION>                                           0
<TOTAL-ASSETS>                                   6,369,588
<CURRENT-LIABILITIES>                            2,401,754
<BONDS>                                            850,000
                                    0
                                         14,089
<COMMON>                                            14,092
<OTHER-SE>                                       3,088,933
<TOTAL-LIABILITY-AND-EQUITY>                     6,369,588
<SALES>                                          4,419,793
<TOTAL-REVENUES>                                 4,419,793
<CGS>                                            1,972,106
<TOTAL-COSTS>                                    1,972,106
<OTHER-EXPENSES>                                    60,203
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                       0
<INCOME-PRETAX>                                   (578,621)
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                               (578,621)
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                      (578,621)
<EPS-BASIC>                                          (0.40)
<EPS-DILUTED>                                        (0.40)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission